All posts tagged Thomas Flaig

  • Molecularly targeted therapies hold promise for many pediatric cancers, but at what cost? Image: Flickr/Cliff1066

    Even after anti-androgen therapy, docetaxel remains useful in prostate cancer

    40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA).

An aging population requires new approaches to prostate cancer care. Image: Flickr/PaulineMak
Matches.jpg
Gold
An aging population requires new approaches to prostate cancer care. Image: Flickr/PaulineMak
Harry Peterson, CU Cancer Center
Image: CannedMuffins/Flickr
Thomas Flaig, MD, University of Colorado Cancer Center
Dr. Thomas Flaig